



KIDS-BCB007-NSP

Clinical Study Report

A Clinical Study of 'GLUTANEX Retinol Eye Cream' on the Improvement of Skin Fine Wrinkles and Relaxation of Freckles and Pigmentation

Date : March 22, 2023

Requested by : Nexus Pharma Co., Ltd. (Korea)

Performed by : Korea Institute of Dermatological Sciences (Korea)



Korea Institute of
Dermatological Sciences

CERTIFICATE FOR RELIABILITY ASSURANCE



Title of the clinical study : A clinical study of 'GLUTANEX Retinol Eye Cream' on the improvement of skin fine wrinkles and relaxation of freckles and pigmentation

Case control No. : KIDS-BCB007-NSP

This study was conducted according to the regulations of designation as the test institution for drugs, quasi-drugs, cosmetics, and medical devices; the guidelines of the management standards for clinical drug evaluations; the guidelines of *in vivo* clinical and *in vitro* evaluation studies; the guidelines of the experimental methods for cosmetic display and advertisements; and the guidelines of the validation of functional cosmetics of the Ministry of Food and Drug Safety, Republic of Korea; the laws of the bioethics and safety of the Ministry of Health and Welfare, Republic of Korea; and the standard operation procedure of the Korea Institute of Dermatological Sciences. All procedures were investigated by the person in charge of reliability assurance.

Title of the clinical study	A clinical study of 'GLUTANEX Retinol Eye Cream' on the improvement of skin fine wrinkles and relaxation of freckles and pigmentation effect				
Date	Step	RA inspection categories	RA inspection result	Approval date	Note
February 06, 2023	Study plan	Reporting plan	Approved	February 06, 2023	
February 14, 2023 ~ March 14, 2023	Performing clinical trial (Measurement progress)	Reporting implementation	Approved	March 14, 2023	
March 15, 2023 ~ March 17, 2023	Analyzing data, Confirming the information on test material	Inspecting raw data	Approved	March 17, 2023	
March 20, 2023 ~ March 21, 2023	Report work	Inspecting draft report	Approved	March 21, 2023	
March 22, 2023	Report final report	Inspecting final report	Approved	March 22, 2023	

This report was prepared on the basis of the experiment results and accurately reflects the data.

March 22, 2023

Scientific Director

In Sook An, Ph. D. (seal)

Reliability Assurance

Ka Ram Kim, Ph. D. (seal)

This report is the confidential document and property of the Korea Institute of Dermatological Sciences; its transfer, plagiarism, and disclosure to third parties is prohibited.

SUMMARY OF THE CLINICAL STUDY



Title of the clinical study	A clinical study of 'GLUTANEX Retinol Eye Cream' on the improvement of skin fine wrinkles and relaxation of freckles and pigmentation	
Clinical trial institution	Korea Institute of Dermatological Sciences 6th Floor, Tower A, 25, Beobwon-ro 11-gil, Songpa-gu, Seoul, 05836, Republic of Korea	
Sponsor	Nexus Pharma Co., Ltd.	
Chief researcher	In Sook An, Ph.D.	
Researcher	Seungbin Kwon, Il Hong, Yun Kim, Minji Jo, Sugyeong Hong, Hyunkyung Kim, Soyeon Park	
Name of the test material	GLUTANEX Retinol Eye Cream	
Trial period	February 06, 2023 (Study initiation) ~ March 22, 2023 (Study termination) For the study initiation, the person in charge of the study signed the clinical study proposal; for the study termination, the person in charge of the study signed the final report.	
Trial period (Measurement period)	February 14, 2023 (First date of visit) ~ March 14, 2023 (End date of visit)	
Inclusion criteria	Female volunteers from twenty five to sixty eight years old who met the inclusion criteria and were not included in the exclusion criteria were selected for this study.	
The age and number of subjects who completed the final study	Twenty one subjects from thirty nine to sixty eight (Average 52.00, Standard deviation 7.61) of female	
Methods	Usage of test material	Each subject applied the same amount of test material 'GLUTANEX Retinol Eye Cream' evenly on the both orbital region and allowed it to be fully absorbed after cleansing twice a day, in the morning and in the evening, during the four weeks test period.
	Evaluations	The evaluations were conducted by Standard Operating Procedures of KIDS and all of the procedures were investigated by the person in charge of reliability assurance. 1. Measurements 1) Evaluation using ANTERA 3D to assess the skin fine wrinkles improvement 2) Evaluation using ANTERA 3D to assess the relaxation of freckles and pigmentation 2. Evaluation of abnormal skin response 3. Survey

This report is the confidential document and property of the Korea Institute of Dermatological Sciences; its transfer, plagiarism, and disclosure to third parties is prohibited.



Results	<ol style="list-style-type: none">1. The evaluation results of skin fine wrinkles using ANTERA 3D The Wrinkles small value indicating skin wrinkles was decreased 12.39% after four weeks of the test material application in comparison with the pre-application ($p < .001$).2. The evaluation results of relaxation of freckles and pigmentation using ANTERA 3D The melanin value indicating freckles and pigmentation was decreased 1.46% after four weeks of the test material application in comparison with the pre-application ($p < .05$).3. Subjects' abnormal skin responses were not detected during the trial period.
Conclusion	In the study requested by Nexus Pharma Co., Ltd., 'GLUTANEX Retinol Eye Cream' was found to be helpful with improving skin fine wrinkles and relieving freckles and pigmentation.

This report is the confidential document and property of the Korea Institute of Dermatological Sciences; its transfer, plagiarism, and disclosure to third parties is prohibited.